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during the same time frame is beyond the scope of this
observational study.
Our study highlights the fact that isoprostane concen-
trations have the same limitations as other measures of
obstetric outcome, such as pH and Apgar score: i.e., they
are increased in neonates with HIE, but may also be
increased in apparently healthy infants and may be
within reference values in infants who die from acute
causes or in whom a pathology manifests after delivery.
We are grateful to all medical and nursing staffs in the
labor wards and neonatal units at Prince of Wales Hospi-
tal, The First Affiliation Hospital of Medical College of
Jinan University, and The Women’s & Children’s Hospital
of Guangdong Province for case recruitment and sample
collection. The study was supported by the Hong Kong
Special Administration Region Research Grant Council
(CUHK4329/99M). All contributors and guarantors in
this study are independent from the funding agency, and
the views expressed here are those of the authors. This
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The clinical relevance of B-type natriuretic peptide (BNP)
as a diagnostic tool and prognostic marker in patients
with cardiovascular diseases has been confirmed recently
(1–3). Over the last 5 years, several immunoassay meth-
ods for the measurement of BNP, which share some
analytical characteristics, such as full automation, turn-
around time 60 min, lower imprecision, and/or better
analytical and functional sensitivity, have become com-
mercially available (1, 4). The analytical performance and
diagnostic accuracy of immunoassays for BNP were com-
pared recently (5, 6). In the present study, we evaluated
the analytical performance and diagnostic accuracy of an
automated immunochemiluminescent assay for BNP
(ACCESS System; Beckman Coulter). We also compared
its performance and accuracy with the TRIAGE BNP test
(Biosite). The 2 immunoassays use as antigen the intact
BNP 1–32 peptide and the same mouse anti-human BNP
antibodies. The capture antibody (Scios) recognizes the
peptide ring, whereas the detection antibody (Biosite)
recognizes an epitope between amino acids 5 and 10 at the
NH2 terminus (6, 7). All statistical analyses were per-
formed by use of parametric tests after log transformation
of the original data. Nonparametric tests were also per-
formed and showed identical statistical trends.
We collected blood samples from 91 healthy individu-
als [51 women and 40 men; mean (SD) age, 43.2 (13.4)
years; range, 16–71 years] and 214 patients with idio-
pathic or secondary cardiomyopathy (only 21 with a left
ventricular ejection fraction 50%). Blood was collected
between 0800 and 0900 after the individuals had fasted
overnight and had rested for 20 min in a supine position.
Immediately after withdrawal, blood samples (8–10 mL)
were placed in ice-chilled disposable polypropylene tubes
containing EDTA (1 mg/mL of plasma). Plasma samples
were obtained shortly after venipuncture by centrifuga-
tion for 15 min at 4 °C and then were frozen and stored at
20 °C in 0.5-mL aliquots until being assayed.
We found that plasma samples can be kept at 37 °C for
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4 h without a significant decrease in measured (on an
ACCESS system) BNP concentration [mean (SD) mea-
sured value, 97.8 (5.3)% of the original concentration;
mean difference from the original concentration, 10.3 ng/L;
95% confidence interval (CI), 20.4 to 41.1 ng/L (P 
0.1147); median measured value, 790 ng/L (range, 37–2904
ng/L); n  15]. We observed a slight but significant differ-
ence when plasma samples were kept at 4 °C for 24 h [mean
measured value 89.0 (5.0)% of the original concentration;
mean difference from the original concentration, 27.5 ng/L;
95% CI, 13.7–41.4 ng/L (P 0.0001); median measured
value, 160.5 ng/L (range, 12–824 ng/L); n  24].
We assessed the detection limit of the ACCESS by
repeatedly measuring (n  20) the calibrator with a BNP
concentration of 0 ng/L in 3 different runs. The mean (SD)
measured concentration was 0.3 (0.1) ng/L (range, 0.3–0.4
ng/L). We confirmed the results of a previous study from
our laboratory indicating that the detection limit of the
TRIAGE is 8 ng/L (manufacturer-reported detection
limit, 5 ng/L) (8 ). The imprecision profiles of the TRIAGE
and ACCESS, obtained by repeated measurements over
20 different days of several plasma samples (7 on the
TRIAGE and 12 on the ACCESS) with BNP concentrations
covering the analytical working range, are shown in Fig.
1A. According to the IFCC goals for desirable (15% total
CV) and optimum (10% total CV) imprecision (7 ), the 2
methods had similar functional sensitivities (10 ng/L
and 30 ng/L, respectively). The imprecision for samples
with BNP values 10 ng/L was not satisfactory in either
method. We assessed the within-run and total imprecision
of the ACCESS according to the NCCLS EP5-A guideline
(including experimental protocol, number of measure-
ments, and data calculation) (9 ) by repeatedly assaying 2
plasma samples with BNP concentrations of 52.6 and 1095
ng/L in duplicate on 20 different working days (both in
the morning and in the afternoon). For the 2 samples,
within-run imprecision was 3.4% and 1.6%, respectively,
and total imprecision was 8.4% and 5.9%.
After exclusion by statistical analysis of the 17 samples
with BNP values 5 ng/L in the TRIAGE assay, we found
a close linear relationship (R  0.919; n  287) between the
2 methods: ACCESS 62.5 (14.1) 0.932 (0.024) TRIAGE (P
0.0001 for both). The Bland–Altman plot of the same data
confirmed that there was a difference between the values
measured with the 2 immunoassays; this difference in-
creased proportionally as the measured concentration in-
creased (Fig. 1B) (10). There was a slight but significant
mean difference between the values [mean (SD) difference
for TRIAGE  ACCESS, 45.2 (217.8) ng/L (minimum–
maximum, 1152 to 1667 ng/L; P 0.0001); mean %
difference,0.2% (minimum–maximum,2.0% to 1.7%)].
All 91 healthy persons were nonobese, normotensive,
and free from acute or chronic diseases. Moreover, all had
values within the reference intervals for creatinine, urea,
glucose, uric acid, albumin, electrolytes, cardiac markers,
and hemoglobin as well as for erythrocyte and leukocyte
Fig. 1. Total imprecision profiles (A) and Bland–Altman difference plot
(B) for the tested immunoassays.
(A), the CV values corresponding to desirable imprecision (15% CV) and optimum
imprecision (10% CV), respectively, are indicated with dashed lines. (B), the
difference plot shows the difference between methods as a percentage (y axis)
plotted vs the mean value (x axis). Solid horizontal lines indicate the mean
difference and the 	 3 SD values. The dashed line indicates no difference.
Table 1. Characteristics of the heart failure patients
enrolled for the evaluation of diagnostic accuracy.
All
NYHA class
I-II III-IV
No. of patients 193 122 71
Mean (SD) age, years 64 (13) 62 (13) 67 (12)
F/M, n 45/148 28/94 16/55
Mean (SD) BMI,a kg/m2 26 (4) 27 (2) 25 (3)
Idiopathic/postischemic/
secondary cardiomyopathy,
%
49/36/15 57/26/17 37/51/12
Mean (SD) LVEF, % 34 (10) 37 (11) 27 (7)
Diabetes, % 14 11 18
Treatment, %
Frusemide 84 36 75
Beta-blockers 71 64 79
ACE inhibitor 78 79 77
ARB 7 4 12
Spironolactone 32 16 59
a BMI, body mass index; LVEF, left ventricular ejection fraction; ACE, angio-
tensinogen-converting enzyme; ARB, angiotensin receptor blocker.
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counts and basic urine analysis. All were asymptomatic
and underwent a complete examination by a cardiologist,
including a visit, standard 12-lead electrocardiogram,
Doppler echocardiographic examination, and a bicycle
stress test (when older than 50 years), which excluded
silent heart disease. The median ACCESS and TRIAGE
BNP concentrations were 10.5 ng/L (range, 1–53 ng/L;
97.5th percentile, 45 ng/L) and 8.9 ng/L (range 5 to 52
ng/L; 97.5th percentile, 35 ng/L), respectively. The distri-
bution of BNP values measured by the 2 methods in the
healthy group is shown in Fig. 1 of the Data Supplement
that accompanies this Technical Brief at http://www.
clinchem.org/content/vol51/issue7/.
To evaluate the diagnostic accuracy of the 2 methods, we
measured only samples from the 193 patients with a clini-
cally ascertained diagnosis of heart failure. The clinical
characteristics of these patients are reported in Table 1.
Cardiac morphology and function were assessed by 2-di-
mensional echocardiography, or cardiac catheterization
when needed. The median (range) ACCESS and TRIAGE
BNP concentrations measured were 171 (2–4833) ng/L and
118 (5 to 4930) ng/L, respectively. The distributions of
BNP values measured by the 2 methods in these patients
grouped according to the severity of heart failure [New York
Heart Association (NYHA) functional classes I to IV] are
shown in Figs. 1 and 2 of the online Data Supplement.
However, the results obtained with both the TRIAGE and
ACCESS indicated a significant difference between the mean
BNP values in healthy persons vs heart failure patients (P
0.0001 by Scheffe` test after ANOVA).
We used ROC curve analysis to evaluate the diagnostic
accuracy of the 2 methods in differentiating between
healthy persons and patients with heart failure. We found
no difference in diagnostic accuracy between the 2 meth-
ods for differentiating healthy persons from patients with
mild (NYHA class I and II; n  122; P  0.196) or severe
(NYHA class III and IV; n  71; P  0.697) heart failure.
For the TRIAGE, the areas under the curves were 0.840
(SE, 0.027; 95% CI, 0.788–0.893) for patients with mild
disease and 0.998 (SE, 0.002; 95% CI, 0.995–1.000) for
patients with severe heart failure, whereas for the
ACCESS system, the areas under the curves were 0.870
(SE, 0.023; 95% CI, 0.825–0.916) for patients with mild
disease and 0.997 (SE, 0.002; 95% CI, 0.993–1.000) for
patients with severe heart failure. The BNP values corre-
sponding to a sensitivity of 95% in differentiating healthy
persons from patients with mild heart failure were 7.5
ng/L (corresponding specificity, 40%) for the ACCESS
and 5.1 ng/L for the TRIAGE (corresponding specificity,
29%). The BNP values corresponding to a specificity of
95% were 41 ng/L (corresponding sensitivity, 65%) for the
ACCESS and 29 ng/L (corresponding sensitivity, 63%) for
the TRIAGE (Fig. 3 of the online Data Supplement).
However, it is important to emphasize that the 95%
sensitivity with the TRIAGE was obtained at a cutoff near
the assay detection limit. The decision cutoff values from
the current study are strictly related to our specific clinical
setting, comparing healthy persons and patients with
clinically ascertained heart failure. In routine clinical
practice, several groups of individuals/patients suspected
of having a specific disease are usually compared.
The present data confirm and extend previous results
suggesting that BNP results are method dependent and that
a single predefined common cutoff value cannot be used
(5, 6). Furthermore, we demonstrated that immunoassays
that use the same antibodies and calibration materials do not
automatically give the same results. However, the cutoff and
reference values of these 2 methods are similar.
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Hyperglycosylated human chorionic gonadotropin (hCG)
is a variant of hCG with more asparagine (N)-linked
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